In the following video, Fool contributor Maxx Chatsko reviews the biggest catalysts for Regeneron's (REGN 0.33%) recent climb and near-rendezvous with $300 per share. The emerging biotech powerhouse has treated investors well in recent years -- returning more than 1,200% since 2008. While the company no doubt has a promising future, investors may be curious if things are getting too hot too fast. Did investors overreact to prior developments this year? Are shares priced for perfection? Or is $300 per share a benchmark that is actually within reach? The key lies in the pipeline.